Riyadh – Asdaf News:
In a strategic move to expand its regional footprint, Dar Al Dawa Development Company has obtained an investment license from Saudi Arabia’s Ministry of Investment paving the way for a new, technologically advanced pharmaceutical facility. This cutting-edge pharmaceutical factory in the Kingdom, complements its existing operations in Jordan and Egypt.
By bolstering its production capacity, Dar Al Dawa aims to address the growing healthcare demands across the region.
Dr. Akram Jarrab, Chairman of the Board of Directors, emphasized: “This achievement reflects our dedication to producing innovative pharmaceutical solutions. We are committed to delivering high-quality healthcare products and expertise to the Saudi market, benefiting patients and caregivers alike.”
CEO Khaled Harb added: “This is a proud moment for Dar Al Dawa, as it reinforces our strong presence in the Saudi market, one of the most strategic in the region. With this expansion, we aim to introduce new pharmaceutical solutions tailored to local and global healthcare needs. Our vision is rooted in providing reliable, impactful healthcare solutions that truly make a difference in society.”
Founded in 1975, Dar Al Dawa is one of the most esteemed pharmaceutical companies in the Middle East. The company operates seven state-of-the-art factories across Jordan and Algeria and exports its products to more than 50 countries worldwide. With a steadfast commitment to sustainability and adherence to international standards, Dar Al Dawa continues to set benchmarks in quality and innovation within the pharmaceutical sector.
